117 related articles for article (PubMed ID: 8309439)
1. Photon contribution to tumor dose from considerations of 131I radiolabeled antibody uptake in liver, spleen, and whole body.
Johnson TK; Colby SB
Med Phys; 1993; 20(6):1667-74. PubMed ID: 8309439
[TBL] [Abstract][Full Text] [Related]
2. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.
Fujimori K; Fisher DR; Weinstein JN
Cancer Res; 1991 Sep; 51(18):4821-7. PubMed ID: 1893374
[TBL] [Abstract][Full Text] [Related]
3. On the possibility of 'real-time' Monte Carlo calculations for the estimation of absorbed dose in radioimmunotherapy.
Johnson TK; Vessella RL
Comput Methods Programs Biomed; 1989 Jul; 29(3):205-10. PubMed ID: 2776457
[TBL] [Abstract][Full Text] [Related]
4. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues.
Maraveyas A; Myers M; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1020-7. PubMed ID: 7866985
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
Badger CC; Davis J; Nourigat C; Wu ZM; Hui TE; Fisher DR; Shulman H; Appelbaum FR; Eary JF; Krohn KA
Cancer Res; 1991 Nov; 51(21):5921-8. PubMed ID: 1682038
[TBL] [Abstract][Full Text] [Related]
7. Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma.
Laitinen JO; Tenhunen M; Kairemo KJ
Nucl Med Commun; 2000 Apr; 21(4):355-60. PubMed ID: 10845224
[TBL] [Abstract][Full Text] [Related]
8. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
9. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
[TBL] [Abstract][Full Text] [Related]
15. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
16. A Monte Carlo approach to patient-specific dosimetry.
Furhang EE; Chui CS; Sgouros G
Med Phys; 1996 Sep; 23(9):1523-9. PubMed ID: 8892249
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
[TBL] [Abstract][Full Text] [Related]
19. Can occult metastases be treated by radioimmunotherapy?
Dunn RM; Juweid M; Sharkey RM; Behr TM; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2656-9. PubMed ID: 9406721
[TBL] [Abstract][Full Text] [Related]
20. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
